Physician profile
Dany Morel
NPI 1497910202
$1,146.69
in general payments reported to CMS, 2019-2025
11 companies · $107 in 2025
The $107 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.77 · 2021: $122 · 2023: $329 · 2024: $567 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $240.96 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.83 | 2021-2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $190.14 | 2023-2024 | Ultomiris, Soliris |
| Pfizer INC. | $122.90 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $108.51 | 2024-2025 | Zerbaxa, Dificid, Prevymis |
| La Jolla Pharmaceutical Company | $80.63 | 2024 | Giapreza, Xerava |
| Aimmune Therapeutics, INC. | $64.43 | 2023 | |
| Tetraphase Pharmaceuticals, INC. | $45.37 | 2025 | |
| Ceribell, INC. | $24.53 | 2025 | Pocket Eeg Device |
| Gilead Sciences, INC. | $16.01 | 2023 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $15.38 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dany Morel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.